Cancer Research UK picks Jones to replace Lane
This article was originally published in Scrip
Executive Summary
Cancer Research UK has appointed Professor Nic Jones Chief Scientist as from 1 February 2011. Professor Jones, currently Director of Cancer Research UK's Paterson Institute within the University of Manchester, is succeeding Professor Sir David Lane, who is currently leading a pioneering research team in Singapore and will continue to advise the charity on its research strategy as an ongoing member of its scientific strategy advisory group. Professor Jones will step down as the Paterson Institute's Director but will continue to lead his research group at the Paterson which studies how cells respond to sudden adverse changes in their surroundings, known as 'environmental stress'. He will also continue in his role as Director of the Manchester Cancer Research Centre
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.